Worst case: $50 mill upfront, but commitment to meet all the costs of the Phase 3. $250 m on FDA approval, 10% royalties
Best case: More upfront, additional commitments to fully fund manufacturing and toxicity etc and European and other non-US approval applications/negotiations – leaving Neuren free to spend any upfront, milestone and royalties on other indications etc
Worst case: $50 mill upfront, but commitment to meet all the...
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.38 |
Change
-0.270(1.98%) |
Mkt cap ! $1.710B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.11 | $4.283M | 320.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $13.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.40 | 3328 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |